Meningitis Vaccines Market

The global market of meningitis vaccine stood at USD 12,783.1 Million in 2018 and is expected to reach USD 27,522.5 Million by the end of 2027, expanding at a CAGR of 8.9% over the forecast period i.e. 2019-2027. The advancements in meningitis vaccine and growing healthcare sector globally is anticipated to further boost the demand for meningitis vaccine in future.

Geographically, North America accounted for the largest market share of 41.2% in 2018 in the revenue of meningitis vaccine market globally. The market of North America region is expected to continue its dominance over the forecast period on the back of rising demand for efficient disease preventive Vaccine across the region.

Robust research and development are going on in healthcare sector to manufacture advanced and cost-effective meningitis Vaccine. The advanced meningitis vaccine further provides precise and accurate dosing with minimalist side effects to the vaccinated population.

The adoption of advanced and high end Vaccine is rising in developing regions such as India, China, Japan and others. To gain a competitive edge, different manufacturers of medical equipment have come up with various new Vaccine to effectively aid in the prevention of meningitis.

With USD 5,999.9 Million revenue by the end of 2027 in the global market, Asia-Pacific Meningitis Vaccine market is expected to showcase lucrative growth over the forecast period. This growth is primarily attributed on the back of increasing governing regulatory body initiatives in order to reduce the number of deaths caused to meningitis across the region.

With the increasing focus of people on healthcare, the Asia-Pacific meningitis vaccine market is expected to witness rapid growth throughout the forecast period. Asia-Pacific market is expected to expand at a CAGR of 9.4% over the forecast period and expected to contribute a market share of 21.8% in global meningitis vaccine market.

Additionally, favorable government initiatives to develop the healthcare infrastructure coupled with increasing healthcare expenditure across the globe is envisioned to bolster the growth of the meningitis Vaccine market robustly over the forecast period.

Moreover, Europe is estimated to grow at a CAGR of 8.7% over the forecast period contributing a market share of 25.6% in the year 2027 in the global meningitis market.

Some of the leading manufacturers in this market are Sanofi Pasteur, GSK, Pfizer, Merck and Essilor among others.